Merus’s Promising Clinical Developments and Strategic Advancements Reinforce Buy Rating with $67 Target

Merus (MRUS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on February 28. Analyst John Newman from Canaccord Genuity maintained a Buy rating on the stock and has a $67.00 price target.

John Newman has given his Buy rating due to a combination of factors including the promising developments in Merus’s clinical trials. The company is making significant progress with petosemtamab, particularly in head and neck squamous cell carcinoma (HNSCC), where it has received breakthrough therapy and fast-track designations. This is expected to lead to positive updates in the first half of 2025, enhancing the drug’s commercial potential.
Moreover, Merus is nearing the completion of enrollment for its Phase 3 registrational trials by the end of 2025, which further supports the positive outlook. Additionally, the potential for petosemtamab in metastatic colorectal cancer could serve as a significant catalyst, given its ability to target LGR5. These factors collectively underpin the reiterated Buy rating and the price target of $67.

In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $84.00 price target.

MRUS’s price has also changed slightly for the past six months – from $51.770 to $47.090, which is a -9.04% drop .